SDZ.SW Sandoz at CHF67.22 on 24 Feb 2026: earnings due 25 Feb will test margins
SDZ.SW stock is trading at CHF67.22 on 24 Feb 2026, within a day range of CHF66.30–CHF67.96 as investors position ahead of Sandoz Group AG’s earnings report due 25 Feb 2026. The group’s EPS of CHF0.40 and a high PE of 165.90 set a high bar for guidance. Today’s intraday volume is 790,251 versus an average of 740,380, signalling focused interest. We highlight the valuation gap with Swiss healthcare peers, near-term catalysts, and a Meyka AI forecast that frames upside and downside scenarios.
SDZ.SW stock: earnings schedule and expectations
Sandoz (SDZ.SW) reports results on 25 Feb 2026 (earnings announcement timestamp). Analysts and traders will watch margins, EPS drivers and any comment on biosimilars demand. The company shows EPS CHF0.40 and the market currently prices that into a PE of 165.90, so management guidance will be the main intraday catalyst.
Quarterly results snapshot: revenue, margins and cash flow
Trailing metrics show revenue per share CHF21.58 and an operating profit margin of 17.48%. Free cash flow per share is CHF0.73 and operating cash flow per share is CHF2.20, indicating cash generation but limited free cash conversion. Working capital and inventory cycles remain long, with days inventory on hand at 225.58 days, a factor to watch in the report.
Valuation versus Swiss healthcare peers and risks
Sandoz’s valuation is stretched versus the Swiss healthcare average PE of 35.08. SDZ.SW’s price-to-sales ~3.96 and price-to-book ~4.20 show a premium to peers like Roche. For sector context see the Roche market page for recent moves and comparisons source. Higher PE reflects expected growth in biosimilars but raises sensitivity to weaker guidance.
Intraday technicals and market action
Momentum indicators are constructive: RSI 64.49 and MACD histogram 0.27 while ADX at 37.36 signals a strong trend. Price sits near the year high CHF67.98 with Bollinger upper band CHF68.66, suggesting limited room before volatility increases. Volume 790,251 (vs avg 740,380) supports the move but traders should monitor intraday liquidity.
Meyka AI rates and forecast for SDZ.SW stock
Meyka AI rates SDZ.SW with a score of 68.43 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a yearly target CHF81.59, implying an upside of 21.37% vs the current CHF67.22. Shorter-term model points: monthly CHF54.91 (downside -18.31%) and quarterly CHF63.47 (downside -5.58%). Forecasts are model-based projections and not guarantees.
Catalysts and risks to watch in the earnings report
Key catalysts: guidance on biosimilars rollout, margin trajectory, and pricing in generics. Risks include pricing pressure in core generics, longer inventories, and interest on net debt (net debt to EBITDA elevated). Management tone on capital allocation and dividend policy will drive the immediate trading reaction.
Final Thoughts
Sandoz Group AG (SDZ.SW) enters its 25 Feb 2026 earnings report with the stock at CHF67.22, trading close to the year high and carrying a stretched PE of 165.90 relative to the Swiss healthcare average. The report will likely pivot the market between two scenarios: a beat with tightened guidance for biosimilars could validate Meyka AI’s yearly forecast CHF81.59 (implied upside 21.37%). A cautious guide or margin slip could push price toward shorter-term model levels like CHF63.47 (implied downside -5.58%) or the monthly scenario CHF54.91. Our view frames SDZ.SW stock as a hold into earnings for investors watching valuation risk, cash conversion and management commentary. Meyka AI, an AI-powered market analysis platform, flags the stock’s operational strengths but notes valuation sensitivity. Forecasts are model projections and not guarantees; position sizing should reflect high PE and inventory cycle risks.
FAQs
When does Sandoz report earnings and why does it matter for SDZ.SW stock?
Sandoz reports on 25 Feb 2026. The earnings release matters because guidance on biosimilars, margins and cash flow will likely move SDZ.SW stock intraday and set the tone for near-term valuation changes.
What is Meyka AI’s price forecast for SDZ.SW stock and the implied upside?
Meyka AI’s yearly forecast for SDZ.SW stock is CHF81.59, implying an upside of 21.37% versus the current CHF67.22. Forecasts are model-based projections and not guarantees.
Which valuation metrics should investors watch in the report for SDZ.SW stock?
Watch EPS (CHF0.40), gross and operating margins, free cash flow conversion and the PE of 165.90. Also compare price-to-sales (~3.96) and price-to-book (~4.20) against peers to judge re-rating risk.
How liquid is SDZ.SW stock for intraday trading?
Intraday volume today is 790,251, above the average 740,380, offering reasonable liquidity on SIX. Still use tight risk controls near the earnings release, as volatility can spike.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.